Study Shows HK L-137 Reduces Inflammation in Healthy Overweight Individuals — Takes Front Line Against Metabolic Syndrome
7.1.2020 15:45:00 EET | Business Wire | Press release
There’s a reason why the health-conscious focus has turned toward foods, supplements and behaviors to reduce inflammation. It’s why House Wellness Foods has put decades of meticulous research into the anti-inflammatory benefits of its unique immunobiotic Lactobacillus plantarum HK L-137, the primary ingredient of its Immuno-LP20®. A just-published study illuminates how this bacillus, in its nonviable form, can be especially important, even lifesaving, to those contending with obesity.
Inflammation is a bodily response we rely on to counter stress, infection and external toxins. But we know that it is also one of the keystones of metabolic dysfunction. Many have gone as far as to suggest that inflammation is the defining characteristic of all infirmity, including the depredating aspects of the aging process itself, leading to eventual organ failure. Unchecked, it can cause the decline of overall health, is linked to a string of metabolic complications, and implicated in dozens of autoimmune diseases from lupus to MS.
Notably, even otherwise healthy individuals under the stress associated with high body mass can suffer a rapidly deteriorating downward spiral; and as we know, obesity is among the most prevalent disease factors in post-industrial society worldwide, (affecting about 40 percent of the U.S. population alone). Simply put, production of inflammatory cytokines increases in individuals carrying more body fat. Though the popular literature avoids the harsh details, the manifestation of this destructive cycle includes insulin resistance, type 2 diabetes, non-alcoholic fatty liver disease, cardiovascular disease, hypertension, and dyslipidemia.
The new study from House Wellness Foods laboratories, in cooperation with the Medical Institute of Bioregulation, Kyushu University, describes in detail the process by which inflammation sets its destructive effects in motion. Adipose tissue produces an abundance of inflammatory cytokines, resulting in elevated serum levels of inflammatory mediators (C-reactive protein and leukocyte concentration among them). Tumor necrosis factor and interleukin induce systemic insulin resistance and affect lipid metabolism. There is a concomitant elevation of the serum levels of triglycerides and very-low-density lipoprotein (VLDL).
In the inflammation response, cells communicate via extraordinarily complex means to protect muscles and organs in bodies subjected to ordinary stress or injury. The research paper defines the consequences of lingering inflammation, such as that associated with overweight, and how the inflammatory mediators present in obese or overweight persons need to be suppressed to thwart associated metabolic disorders such as insulin resistance and hyperlipidemia.
Lactic acid-based bacterial probiotics have long shown effectiveness in immune modulation and lipid metabolism. Viable lactobacilli in foods like kefir and other probiotic boosters have proved valuable in lowering total cholesterol levels, but their effect is limited both by their chemistry and the mechanisms by which they act on the body. Multiple peer-reviewed studies have shown that nonviable bacilli, like (heat-killed) HK L-137, are equally, and in many instances more effective in improving obesity-induced inflammation and abnormalities of lipid metabolism, with a more profound impact on immune response as gauged by multiple measurements including enhanced Th1-related immune functions, such as concanavalin A (Con A)-induced proliferation in T cell production.
Heat-killing’s advantage is that it strengthens the bacterial organism’s cellular barriers and fixes its biogenetic material. It stands up to gastric fluids and remains intact through to the ileum of the small intestine, to go on to spur immune response in the mucosa. Heat-killing is what gives HK L-137, the prime constituent of House’s Immuno-LP20, its character as an immunobiotic, and as multiple peer-reviewed studies show, its cell protective and regenerative function supports quality of life improvements that include dramatic reduction of upper respiratory infection and periodontal disease. It also makes HK L-137 available for the widest range of applications due to its ability to withstand processing. Nonviability gives it an unparalleled shelf life without diminishing its effectiveness.
House Wellness Foods has devoted nearly 30 years to both the clinical study of the immunological and protective properties of HK L-137, and the refinement of its natural, food product-based production. The apex of its efforts is Immuno-LP20®, its functional immunobiotic based on HK L-137.
Metabolic syndrome is a crisis of global proportion. Countering it, House Wellness Foods, in its supplements and functional food products, has concentrated its focus on supporting the body’s innate ability to bolster immunity and restore vitality at the cellular level. It is a quest for nothing less than the sustenance of superior health and vigor, and the extension of all life on the planet.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200107005127/en/
Contact information
Kotaro Soga
House Wellness Foods Corp.
s-hirayama@housefoods.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
